These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7122454)

  • 1. [Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].
    Kudriavtsev IA; Paramonova TD; Golenko OD; Miasishcheva NV
    Probl Gematol Pereliv Krovi; 1982 Jul; 27(7):27-31. PubMed ID: 7122454
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cellular mechanism of the antileukemic action of quinoline dibromide].
    Golenko OD; Paramonova TD; Nikolaeva TG
    Biull Eksp Biol Med; 1984 Jul; 98(7):59-61. PubMed ID: 6466833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 4. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
    Naujokaitis SA
    Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 6. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 8. [Morphogenesis of experimental neuroleukemia].
    Petrov SA
    Arkh Patol; 1994; 56(2):25-7. PubMed ID: 8037587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
    Neil GL; Homan ER
    Cancer Res; 1973 Apr; 33(4):895-901. PubMed ID: 4696483
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system.
    Allen TM; Mehra T
    Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575
    [No Abstract]   [Full Text] [Related]  

  • 11. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancerostatic effect of some fluorenone azomethines tested against leukemia L 1210 (author's transl)].
    Jungstand W; Gutsche W; Wohlrabe K; Schulze W
    Arch Geschwulstforsch; 1979; 49(1):15-7. PubMed ID: 444028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
    Lee SH; Caron N; Kimball AP
    Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytokinetic effects of 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5- dioxopiperazin-1-yl) ethane (MST-16) on leukemia L1210 cells in mice].
    He H; Wang MY; Zhang TM
    Zhongguo Yao Li Xue Bao; 1988 Jul; 9(4):369-73. PubMed ID: 3195349
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
    Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
    Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platinum(II) choline complex on murine leukemias L1210 and P388.
    Ochocki J; Glinka R; Cieśliński M; Góra-Tybor J; Potemski P
    Pharmazie; 1997 Jul; 52(7):567-9. PubMed ID: 9266598
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential antitumor agents. VI. Bisquaternary salts.
    Atwell GJ; Cain BF
    J Med Chem; 1968 Mar; 11(2):295-300. PubMed ID: 5663621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.